Review
Andrology
Young Jin Tak, Sang Yeoup Lee
Summary: Obesity has a greater negative impact on the health of men, with pharmacotherapy showing potential for significant weight loss. However, there are concerns about high costs and potential adverse effects associated with anti-obesity drugs, requiring careful consideration by patients before initiating treatment.
WORLD JOURNAL OF MENS HEALTH
(2021)
Review
Endocrinology & Metabolism
Alexandra Tsankof, Georgios Neokosmidis, Evgenia Koureta, Stavroula Veneti, Evangelos Cholongitas, Konstantinos Tziomalos
Summary: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease that affects a significant portion of the global population. Obesity is a major risk factor for NAFLD, but lifestyle measures rarely lead to substantial and sustained weight loss. Antiobesity agents are considered in the management of NAFLD, but limited data exist on their safety and effectiveness. Glucagon-like peptide-1 receptor agonists, liraglutide and semaglutide, may be a first-line option for obese patients with NAFLD and type 2 diabetes mellitus (T2DM), as they induce significant weight loss and have been extensively studied in T2DM patients. However, more research is needed to evaluate their effects on liver-related and cardiovascular outcomes in NAFLD patients, especially those without T2DM.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Aristea Sideri Gugger, Cara Dimino, Sunil K. Panigrahi, Laurel Mayer, Richard M. Smiley, Judith Korner, Sharon L. Wardlaw
Summary: The study found that Lorcaserin (LOR) affects the brain melanocortin system in humans and is more effective in individuals with lower melanocortin activity.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Endocrinology & Metabolism
Leonardo de Andrade Mesquita, Giovana Fagundes Piccoli, Gabriella Richter da Natividade, Bernardo Frison Spiazzi, Veronica Colpani, Fernando Gerchman
Summary: This study analyzed the association between lorcaserin and cancer risk, suggesting that current evidence does not confirm an increased risk of cancer with lorcaserin, but indicates a trend in this direction.
Article
Endocrinology & Metabolism
Stefany D. Primeaux, Robert Dubin, Frank L. Greenway
Summary: This study aimed to investigate the effects of an orlistat mouth rinse on the intake of a high-fat meal. The results showed that the orlistat mouth rinse decreased total and fat calories consumed during the high-fat meal in high-fat consumers, but did not alter calories consumed in low-fat consumers (P < 0.05).
DIABETES OBESITY & METABOLISM
(2023)
Article
Microbiology
Eun-Ji Song, Na Rae Shin, Songhee Jeon, Young-Do Nam, Hojun Kim
Summary: This study aimed to explore the effects of lorcaserin (LS) and phentermine (PT) on obesity and gut microbiota. The results showed that LS and PT can modulate the composition of gut microbiota and restore gut microbial dysbiosis, which is strongly correlated with obesity-related markers. Additionally, LS and PT increased the mRNA level of G protein-coupled receptor 120 (GPR120) and correlated with obesity-related markers.
FRONTIERS IN MICROBIOLOGY
(2023)
Article
Endocrinology & Metabolism
Yu-Jin Kwon, Go Eun Kwon, Hye Sun Lee, Man Ho Choi, Ji-Won Lee
Summary: Orlistat treatment improves oxysterol metabolism in overweight and obese adults and plays a crucial role in the process of atherosclerosis.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Junjun Chu, Changsheng Xing, Yang Du, Tianhao Duan, Siyao Liu, Pengfei Zhang, Chumeng Cheng, Jill Henley, Xin Liu, Chen Qian, Bingnan Yin, Helen Yicheng Wang, Rong-Fu Wang
Summary: Cellular lipid synthesis is crucial for SARS-CoV-2 replication. Inhibitors of fatty acid synthase, such as the approved anti-obesity drug orlistat, show potential for preventing and treating COVID-19 by inhibiting viral replication.
Article
Biochemistry & Molecular Biology
Zaidatul Akmal Othman, Zaida Zakaria, Joseph Bagi Suleiman, Wan Syaheedah Wan Ghazali, Mahaneem Mohamed
Summary: The study investigated the anti-atherosclerotic effect of orlistat on obesity-induced vascular oxidative stress in male rats. Orlistat treatment significantly improved lipid profiles, increased antioxidant enzymes, and decreased pro-inflammatory markers expressions, suggesting its therapeutic effect in attenuating the progression of atherosclerosis in obesity.
Article
Biochemistry & Molecular Biology
Zaidatul Akmal Othman, Zaida Zakaria, Joseph Bagi Suleiman, Khairul Mohd Fadzli Mustaffa, Nur Asyilla Che Jalil, Wan Syaheedah Wan Ghazali, Ninie Nadia Zulkipli, Mahaneem Mohamed
Summary: This study found that orlistat can mitigate myocardial damage in obese rats by improving oxidative stress, inhibiting inflammation and apoptosis. This is of great significance for understanding the pharmacological effects of orlistat and its application in treating complications related to obesity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Microbiology
Jin Jin, Jiani Wang, Ruyue Cheng, Yan Ren, Zhonghua Miao, Yating Luo, Qingqing Zhou, Yigui Xue, Xi Shen, Fang He, Haoming Tian
Summary: This study aimed to evaluate the possible anti-obesity effects of orlistat and ezetimibe and determine the mechanism by which they alter the composition of gut microbiota and short-chain fatty acids (SCFAs) in mice with a high-fat diet (HFD)-induced obesity. The administration of orlistat and ezetimibe can characteristically influence the body weight and serum lipid metabolism, and glucolipid levels in diet-induced obese mice and is accompanied by significant changes in the gut microbiota and SCFAs.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Pharmacology & Pharmacy
Jin Jin, Ruyue Cheng, Yan Ren, Xi Shen, Jiani Wang, Yigui Xue, Huimin Zhang, Xiuhua Jia, Tingting Li, Fang He, Haoming Tian
Summary: This study investigated the gut microbiota characteristics of obese subjects from Xinjiang, China, and explored the effects of orlistat and ezetimibe medication. The results showed that gut microbiota composition was influenced by geography and dietary habits. The two drugs had limited effects on the overall gut microbial community, with some alterations in low-abundant bacteria.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Guangxu Xu, Ziyi Zhao, Weiya Z. Wysham, Dario R. Roque, Ziwei Fang, Wenchuan Sun, Yajie Yin, Boer Deng, Xiaochang Shen, Chunxiao Zhou, Victoria Bae-Jump
Summary: Obesity is strongly associated with endometrial cancer, with more than 65% of cases attributed to obesity and being overweight. In this study, the effects of dietary intervention and the FAS inhibitor orlistat were examined in a mouse model of endometrial cancer, and it was found that both interventions had anti-tumor activity. These findings support further investigation of orlistat and dietary interventions for the prevention and treatment of endometrial cancer.
FRONTIERS IN ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Ze Wang, Junli Zhao, Xiang Ma, Yun Sun, Guimin Hao, Aijun Yang, Wenchao Ren, Lei Jin, Qun Lu, Gengxiang Wu, Xiufeng Ling, Cuifang Hao, Bo Zhang, Xinyu Liu, Dongzi Yang, Yimin Zhu, Jing Li, Hongchu Bao, Ancong Wang, Jianqiao Liu, Zi-Jiang Chen, Jichun Tan, Yuhua Shi
Summary: The pharmacologic weight-loss intervention with orlistat prior to IVF-ET did not improve live birth rate among overweight or obese women, although it was beneficial for weight reduction.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Ze Wang, Junli Zhao, Xiang Ma, Yun Sun, Guimin Hao, Aijun Yang, Wenchao Ren, Lei Jin, Qun Lu, Gengxiang Wu, Xiufeng Ling, Cuifang Hao, Bo Zhang, Xinyu Liu, Dongzi Yang, Yimin Zhu, Jing Li, Hongchu Bao, Ancong Wang, Jianqiao Liu, Zi-Jiang Chen, Jichun Tan, Yuhua Shi
Summary: Prior pharmacologic-weight-loss intervention with orlistat before IVF-ET did not improve live birth rate among overweight or obese women, but was beneficial for weight reduction.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)